London, 9 July 2025 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its interim financial results for the six months ended 30 June 2025 on Thursday 7 August 2025.

A recording of the presentation will be available on the Group's website at www.hikma.com from 7:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:00am BST, and a recording will be made available on the Company's website.

To join via conference call please dial:

United Kingdom (Local): +44 20 3936 2999
United Kingdom (Toll-Free): ): +44 808 189 0158
Global Dial-In Numbers
Access Code: 358168

- ENDS -

Enquiries      

Hikma Pharmaceuticals PL

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2025 Hikma Pharmaceuticals PLC. All rights reserved.